Effects of anacetrapib in patients with atherosclerotic vascular disease
<p>BACKGROUND Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL chole...
Main Authors: | Bowman, L, Hopewell, J, Chen, F, Wallendszus, K, Stevens, W, Collins, R, Wiviott, S, Cannon, C, Braunwald, E, Sammons, E, Landray, M |
---|---|
Format: | Journal article |
Published: |
Massachusetts Medical Society
2017
|
Similar Items
-
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease
by: Sammons, E, et al.
Published: (2021) -
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
by: Landray, M, et al.
Published: (2017) -
Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans
by: Mathieu R. Brodeur, et al.
Published: (2023-01-01) -
Metabolic Syndrome in Patients with Atherosclerotic Vascular Disease
by: Sadaf Zaman
Published: (2016-06-01) -
Use of secondary preventive medications in patients with atherosclerotic disease in urban China: a cross-sectional study of 16, 860 patients.
by: Li, J, et al.
Published: (2012)